title: Validation of Cross-Species Reactivity of the VEGF-A/PDGFRβ Bifunctional Antibody PF-06653157.
abstract: PF-06653157 is a bifunctional antagonist monoclonal antibody (mAb) that targets human VEGF-A ligand and PDGF-Rβ. With the advent of PF-06653157 as an angiogenesis inhibitor and potential treatment for angiogenesis deregulation diseases, a relevant toxicology species is needed for toxicity and efficacy studies. Investigative studies were conducted to validate the mAb dual antagonist properties in a human system and determine its cross-reactive pharmacology in nonhuman cells.
  
  
  
  Sequence alignment was used to determine percent sequence identity of VEGF and PDGF receptors and ligands; qualitative reverse transcription polymerase chain reaction (qRT-PCR) was used to determine the presence of PDGF-Rβ on cells of interest. The functional activity of PF-06653157 antibody was assessed in human, dog, porcine, rabbit, rat, mouse, and cynomolgus monkey cells treated with VEGF and PDGF ligands through cell proliferation assays and western blot analysis of AKT and p44/p42 (ERK1/2) protein phosphorylation and enzyme-linked immunosorbent assay.
  
  
  
  PF-06653157 attenuated phosphorylation of AKT and p44/p42 proteins in human and cynomolgus monkey cells. The antibody did not attenuate AKT nor p44/p42 phosphorylation in any other species tested. PDGFR signaling could not be activated with human PDGF ligand in the porcine cells, so PF-06653157 activity in porcine remains inconclusive.
  
  
  
  The PF-06653157 mAb cross-reacts with cynomolgus monkey cells in a similar manner to human cells. Therefore, cynomolgus monkeys are considered the appropriate species for efficacy and regulatory toxicology studies in PF-06653157 development.
authors.affiliation: Drug Safety Research and Development , Pfizer, Inc., San Diego, California.
authors.forename: Roshan
authors.initials: R
authors.lastname: Ashoor
authors.affiliation: Drug Safety Research and Development , Pfizer, Inc., San Diego, California.
authors.forename: Dong
authors.initials: D
authors.lastname: Lee
authors.affiliation: Drug Safety Research and Development , Pfizer, Inc., San Diego, California.
authors.forename: Alvan
authors.initials: A
authors.lastname: Cheng
authors.affiliation: Drug Safety Research and Development , Pfizer, Inc., San Diego, California.
authors.forename: Bart
authors.initials: B
authors.lastname: Jessen
authors.affiliation: Drug Safety Research and Development , Pfizer, Inc., San Diego, California.
authors.forename: Wenhu
authors.initials: W
authors.lastname: Huang
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000494:pharmacology; D003429:Cross Reactions / Q000276:immunology*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D000882:Haplorhini; D006801:Humans; D051379:Mice; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D011817:Rabbits; D051381:Rats; D020797:Receptor, Platelet-Derived Growth Factor beta / Q000037:antagonists & inhibitors* / Q000276:immunology* / Q000378:metabolism; D013329:Structure-Activity Relationship; D013552:Swine; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000276:immunology* / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; C000624384:PF-06653157; D042461:Vascular Endothelial Growth Factor A; D020797:Receptor, Platelet-Derived Growth Factor beta
keywords: PDGFRβ; VEGF; angiogenesis; bi-functional antagonist; species reactivity